EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blockade of CCR5 + T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody

Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Bin Zhao, Zhuoyang Shen, Shengtao Hu, Chaomei Zhang, Xiaojun Zhang, Jing Zhang, Yongxiang Yan, Pengfei Zhou und 3 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202408598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Ming Yi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, P. R. China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Antibodies, Bispecific, B7-H1 Antigen, Transforming Growth Factor beta. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the previous studies, anti‐TGF‐β/PD‐L1 bispecific antibody YM101 is demonstrated, with superior efficacy to anti‐PD‐L1 monotherapy in multiple tumor models. However, YM101 therapy can not achieve complete regression in most tumor‐bearing mice, suggesting the presence of other immunosuppressive elements in the tumor microenvironment (TME) beyond TGF‐β and PD‐L1. Thoroughly exploring the TME is imperative to pave the way for the successful translation of anti‐TGF‐β/PD‐L1 BsAb into clinical practice. In this work, scRNA‐seq is employed to comprehensively profile the TME changes induced by YM101. The scRNA‐seq analysis reveals an increase in immune cell populations associated with antitumor immunity and enhances cell‐killing pathways. However, the analysis also uncovers the presence of immunosuppressive CCR5 + T cells in the TME after YM101 treatment. To overcome this hurdle, YM101 is combined with Maraviroc, a widely used CCR5 antagonist for treating HIV infection, suppressing CCR5 + T cell accumulation, and optimizing the immune response. Mechanistically, YM101‐induced neutrophil activation recruits immunosuppressive CCR5 + T cells via CCR5 ligand secretion, creating a feedback loop that diminishes the antitumor response. Maraviroc then cleared these infiltrating cells and offset YM101‐mediated immunosuppressive effects, further unleashing the antitumor immunity. These findings suggest selectively targeting CCR5 signaling with Maraviroc represents a promising and strategic approach to enhance YM101 efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentAntibodies, BispecificB7-H1 AntigenTransforming Growth Factor betaT-LymphocytesAnimalsMiceReceptors, CCR5HumansDisease Models, AnimalMaravirocCCR5 Receptor Antagonists

Stichwörter der Autor:innen

CCR5TGF‐β, PD‐L1bispecific antibodycancer immunotherapycombination therapytumor microenvironment

Substanzen

Antibodies, BispecificB7-H1 AntigenTransforming Growth Factor betaReceptors, CCR5MaravirocCCR5 Receptor Antagonists

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, P. R. China.
  • Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, P. R. China.
  • Department of Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, P. R. China.
  • Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, P. R. China.
  • Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, P. R. China.
  • Wuhan YZY Biopharma Co., Ltd, Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, P. R. China.

ORCID-Profile: Kongming Wu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • China Postdoctoral Science Foundation

Zitieren

APA

Yi, M., Li, T., Niu, M., Wu, Y., Zhao, B., Shen, Z., Hu, S., Zhang, C., Zhang, X., Zhang, J., Yan, Y., Zhou, P., Chu, Q., Dai, Z., & Wu, K. (2024). Blockade of CCR5 + T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody. Advanced Science. https://doi.org/10.1002/advs.202408598

Vancouver

Yi M, Li T, Niu M, Wu Y, Zhao B, Shen Z, et al. Blockade of CCR5 + T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody. Advanced Science. 2024. doi:10.1002/advs.202408598

BibTeX
@article{Yi2024,
  author = {Yi, Ming and Li, Tianye and Niu, Mengke and Wu, Yuze and Zhao, Bin and Shen, Zhuoyang and Hu, Shengtao and Zhang, Chaomei and Zhang, Xiaojun and Zhang, Jing and Yan, Yongxiang and Zhou, Pengfei and Chu, Qian and Dai, Zhijun and Wu, Kongming},
  title = {Blockade of CCR5 + T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202408598}
}
Kostenlos starten →